Oncopeptides AB logo

ONCO - Oncopeptides AB Share Price

SEK120.5 -3.0  -2.4%

Last Trade - 10/05/21

Mid Cap
Market Cap £695.6m
Enterprise Value £625.2m
Revenue £n/a
Position in Universe 405th / 1835
Unlock ONCO Revenue
Relative Strength (%)
1m -13.7%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -44.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 495.5 1,207
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Oncopeptides AB revenues was not reported. Net lossincreased from SEK740.7M to SEK1.59B. Higher net lossreflects Marketng and distributon costs increase fromSEK127.4M to SEK456.5M (expense), Research and developmentcosts increase of 58% to SEK866.2M (expense), Administratveexpenses increase from SEK72M to SEK197.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ONCO Revenue Unlock ONCO Revenue

Net Income

ONCO Net Income Unlock ONCO Revenue

Normalised EPS

ONCO Normalised EPS Unlock ONCO Revenue

PE Ratio Range

ONCO PE Ratio Range Unlock ONCO Revenue

Dividend Yield Range

ONCO Dividend Yield Range Unlock ONCO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ONCO EPS Forecasts Unlock ONCO Revenue
Profile Summary

Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since February 22, 2017
No. of Shareholders: n/a
No. of Employees: 280
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 67,939,715
Free Float (0.0%)
Eligible for
ONCO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ONCO
Upcoming Events for ONCO
Friday 14th May, 2021 Estimate
Oncopeptides AB Annual Shareholders Meeting
Frequently Asked Questions for Oncopeptides AB
What is the Oncopeptides AB share price?

As of 10/05/21, shares in Oncopeptides AB are trading at SEK120.5, giving the company a market capitalisation of £695.6m. This share price information is delayed by 15 minutes.

How has the Oncopeptides AB share price performed this year?

Shares in Oncopeptides AB are currently trading at SEK120.5 and the price has moved by -6.3% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oncopeptides AB price has moved by -27.35% over the past year.

What are the analyst and broker recommendations for Oncopeptides AB?

Of the analysts with advisory recommendations for Oncopeptides AB, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Oncopeptides AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Oncopeptides AB next release its financial results?

Oncopeptides AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Oncopeptides AB dividend yield?

Oncopeptides AB does not currently pay a dividend.

Does Oncopeptides AB pay a dividend?

Oncopeptides AB does not currently pay a dividend.

When does Oncopeptides AB next pay dividends?

Oncopeptides AB does not currently pay a dividend.

How do I buy Oncopeptides AB shares?

To buy shares in Oncopeptides AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oncopeptides AB?

Shares in Oncopeptides AB are currently trading at SEK120.5, giving the company a market capitalisation of £695.6m.

Where are Oncopeptides AB shares listed? Where are Oncopeptides AB shares listed?

Here are the trading details for Oncopeptides AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: ONCO
What kind of share is Oncopeptides AB?

Based on an overall assessment of its quality, value and momentum, Oncopeptides AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oncopeptides AB share price forecast 2021?

Shares in Oncopeptides AB are currently priced at SEK120.5. At that level they are trading at 0.104% discount to the analyst consensus target price of 0.00.

Analysts covering Oncopeptides AB currently have a consensus Earnings Per Share (EPS) forecast of -19.44 for the next financial year.

How can I tell whether the Oncopeptides AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncopeptides AB. Over the past six months, the relative strength of its shares against the market has been -38.47%. At the current price of SEK120.5, shares in Oncopeptides AB are trading at -19.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oncopeptides AB PE Ratio?

We were not able to find PE ratio data for Oncopeptides AB.

Who are the key directors of Oncopeptides AB?

Oncopeptides AB's management team is headed by:

Jakob Lindberg - CEO
Eva Nordstrom - COO
Jonas Brambeck - IND
Jarl Jungnelius - IND
Per Samuelsson - IND
Paula Boultbee - OTH
Christian Jacques - EVP
Brian Stuglik - IND
Per Wold-Olsen - CHM
Anders Martin-Lof - CFO
Jennifer Jackson - IND
Klaas Bakker - EVP
Joseph Horvat - CEX
Karolina Vilval - GCN
Andrea Passalacqua - GMG
Who are the major shareholders of Oncopeptides AB?

Here are the top five shareholders of Oncopeptides AB based on the size of their shareholding:

HealthCap AB Venture Capital
Percentage owned: 15.08% (11.3m shares)
Industrifonden Venture Capital
Percentage owned: 9.88% (7.42m shares)
Fjärde AP-Fonden Pension Fund
Percentage owned: 5.09% (3.82m shares)
C WorldWide Asset Management Fondsmaeglerselskab A/S Investment Advisor
Percentage owned: 4.26% (3.20m shares)
Handelsbanken Asset Management Investment Advisor/Hedge Fund
Percentage owned: 2.8% (2.10m shares)
Similar to ONCO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.